GlaxoSmithKiline seeks authorisation for type-2 diabetes treatment

FTSE-100 listed pharmaceutical giant GlaxoSmithKline (GSK) has submitted a marketing authorisation application (MAA) for its albiglutide treatment to the European Medicines Agency (EMA).

FTSE-100 listed pharmaceutical giant GlaxoSmithKline (GSK) has submitted a marketing authorisation application (MAA) for its albiglutide treatment to the European Medicines Agency (EMA).

The product is an investigational once-weekly treatment for adult patients with type-2 diabetes which is not yet approved anywhere in the world.

The company also made a submission for albiglutide's regulatory application in the US.

Studies of albiglutide have shown that it rapidly degrades GLP-1, a peptide that is normally secreted from the gastrointestinal tract during a meal which in turn helps release insulin to control blood sugar elevations after eating, but which is reduced or absent in a person with type-2 diabetes.

GSK's share price was 0.48% higher at 1,480p by 13:15 Thursday.

NR

Recommended

Share tips of the week – 24 September
Share tips

Share tips of the week – 24 September

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
24 Sep 2021
Three strong Asian stocks trading at bargain prices
Share tips

Three strong Asian stocks trading at bargain prices

Professional investor Nitin Bajaj of the Fidelity Asian Values investment trust picks three stocks that dominate their industries, earn good returns o…
20 Sep 2021
Why it pays to face up to your investment mistakes
Investment strategy

Why it pays to face up to your investment mistakes

Buying stocks can be a complicated business. But selling stocks can be tricky, too – even if you sell for the right reasons. Max King explains how to …
17 Sep 2021
Share tips of the week – 17 September
Share tips

Share tips of the week – 17 September

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
17 Sep 2021

Most Popular

Two shipping funds to buy for steady income
Investment trusts

Two shipping funds to buy for steady income

Returns from owning ships are volatile, but these two investment trusts are trying to make the sector less risky.
7 Sep 2021
Should investors be worried about stagflation?
US Economy

Should investors be worried about stagflation?

The latest US employment data has raised the ugly spectre of “stagflation” – weak growth and high inflation. John Stepek looks at what’s going on and …
6 Sep 2021
The times may be changing, but don’t change how you invest
Small cap stocks

The times may be changing, but don’t change how you invest

We are living in strange times. But the basics of investing remain the same: buy fairly-priced stocks that can provide an income. And there are few be…
13 Sep 2021